stockrow
Saturday 7 November 2026
Export SGMOQ’s income statement to Excel — free account
Sangamo Therapeutics, Inc.
SGMOQ Healthcare Biotechnology
Sangamo Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.6 million, down 31.6% from fiscal 2024.
- Revenue
- −77.6%
- EPS
- +42.9%
- Free cash flow
- +26.2%
Quarter to March 2026, against a year earlier
0.11
0.00
0.00%
Follow SGMOQ
Alert me
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.82 | 2.98 | 6.20 | 1.70 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(5.05) | (4.82) | (7.15) | (7.64) | |
P/B ratio |
0.00 | 0.00 | 32.65 | 7.08 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.82 | 3.15 | 6.11 | 1.57 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.08) | (1.28) | (2.64) | (3.57) | |
EV/FCF |
(1.08) | (1.27) | (2.63) | (3.30) | |
Quick Ratio |
0.54 | 0.50 | 0.62 | 0.81 | |
Current Ratio |
0.70 | 0.84 | 0.88 | 1.05 | |
Net Debt/EBITDA |
0.89 | 0.58 | 0.91 | 2.40 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.47 | 0.49 | 0.33 | 0.86 | |
Operating CF/Net income |
0.62 | 0.65 | 0.82 | 0.91 | |
Capex/Depreciation |
(0.01) | (0.01) | (0.03) | (0.01) | |
Research and Development Expense of Revenue |
1,842.58% | 220.96% | 4,843.72% | 147.95% | |
Selling, General and Administrative Expense of Revenue |
472.82% | 54.53% | 1,375.56% | 49.58% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
68.79% | 14.97% | 366.09% | 12.16% | |
Graham Net Nets |
(0.43) | (0.32) | (0.19) | (0.20) | |
Graham Number |
0.65 | 0.71 | 0.00 | 0.00 | |
Earnings Yield |
(152.00%) | (104.76%) | (65.67%) | (51.85%) | |
Free Cash Flow Yield |
(92.87%) | (83.22%) | (37.53%) | (28.01%) | |
Revenue per Share |
0.00 | 0.05 | 0.00 | 0.07 | |
Operating CF per Share |
(0.05) | (0.09) | (0.09) | (0.07) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.05) | (0.09) | (0.09) | (0.07) | |
Cash per Share |
0.07 | 0.07 | 0.10 | 0.15 | |
Shareholders Equity per Share |
(0.05) | (0.05) | 0.02 | 0.08 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.05) | (0.05) | 0.02 | 0.08 | |
Free Cash Flow |
(19.29) | (24.42) | (28.56) | (18.18) | |
Working Capital |
(16.02) | (6.64) | (6.05) | 2.23 | |
Capital Expenditures |
(0.01) | (0.01) | (0.06) | (0.02) | |
Net Current Asset Value |
(41.81) | (38.18) | (38.32) | (28.06) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.11 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.62 | 0.45 | 5.51 | 0.48 | |
Average Payables |
18.76 | 14.96 | 17.67 | 14.17 | |
Average Assets |
73.07 | 80.69 | 99.95 | 95.29 | |
Average Common Equity |
(7.02) | 4.25 | 22.69 | 21.65 |
Columns are period end dates